NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
NXTC Shareholders Click Here: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=10948&wire=1
MESO Shareholders Click Here: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10948&wire=1
LVS Shareholders Click Here: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=10948&wire=1
* ADDITIONAL INFORMATION BELOW *
Nextcure, Inc. (NASDAQ:NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Lead Plaintiff Deadline : November 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=10948&wire=1
Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
Mesoblast Limited (NASDAQ:MESO)
MESO Lawsuit on behalf of: investors who purchased April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline : December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10948&wire=1
According to the filed complaint, during the class period, Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Las Vegas Sands Corp. (NYSE:LVS)
LVS Lawsuit on behalf of: investors who purchased February 27, 2016 - September 15, 2020
Lead Plaintiff Deadline : December 21, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=10948&wire=1
According to the filed complaint, during the class period, Las Vegas Sands Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: